A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (276 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-08-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: metformindiabetesmellitussyndromepatients
  Phrases that lowered it: participantsparticipanteffect ofindividualsinfection
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports with a death: 8.2% (lowers risk) · Drug's FDA history
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Blinding: quadruple (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 67.5% (lowers risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 408637 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 29233 (raises risk) · Drug's FDA history
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Zofin to Treat COVID-19 Long Haulers NCT05228899 · started 2022 · scored riskier than 87% of active trials completed
• To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID NCT05911009 · started 2023 · scored riskier than 15% of active trials completed
• NE3107 in Adults With Neurological Symptoms of Long COVID NCT06847191 · started 2025 · scored riskier than 83% of active trials completed
• Phase 2 Study of RSLV-132 in Subjects With Long COVID NCT04944121 · started 2021 · scored riskier than 14% of active trials completed
• Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19 NCT04619706 · started 2020 · scored riskier than 35% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.